| Literature DB >> 24422880 |
Anneke van der Zee1, Lieuwe Roorda, Gerda Bosman, Ad C Fluit, Mirjam Hermans, Paul H M Smits, Adri G M van der Zanden, René Te Witt, Lesla E S Bruijnesteijn van Coppenraet, James Cohen Stuart, Jacobus M Ossewaarde.
Abstract
BACKGROUND: Resistance to carbapenem antibiotics is emerging worldwide among Enterobacteriaceae. To prevent hospital transmission due to unnoticed carriage of carbapenemase producing micro-organisms in newly admitted patients, or follow-up of patients in an outbreak setting, a molecular screening method was developed for detection of the most prevalent carbapenemase genes; blaOXA-48, blaVIM, blaIMP, blaNDM and blaKPC.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24422880 PMCID: PMC3897903 DOI: 10.1186/1471-2334-14-27
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Figure 1Standard curve of multiplex PCR. Inferred efficiencies of multiplex amplification range from 82% for IMP, to 85% for VIM.
Figure 2A) Amplification plot of VIC labelled PCR products of VIM, NDM, and KPC (protocol 1), and B) OXA-48/CTX-M and VIM/IMP (protocol 2). Reactions were performed in the presence of the internal control PhHV. For clarity, a selection of strains is shown. OXA-48 positives with lower plots were also positive for CTX-M.
Multi-centre comparison of the PCR assay for detection of carbapenemases, and the PCR platforms, and DNA polymerases used
| OXA 8-90 | OXA-48 | OXA-48 | OXA-48 | OXA-48 | OXA-48 | OXA-48 | OXA-48 |
| OXA 8-17 | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48 | OXA-48 | OXA-48 |
| S 4-2 | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48 | OXA-48 | OXA-48 |
| S3-60 | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48/CTX-M | OXA-48 | OXA-48 | OXA-48 |
| GR-21/PM-302 | VIM | VIM | VIM | VIM | VIM | VIM | VIM |
| GR-04/KP-69 | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC |
| GR-38/KP-139 | VIM | VIM | VIM | VIM | VIM | VIM | VIM |
| GR-31/KP-956 | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC | VIM/KPC |
| GR-23/KP-385 | KPC | KPC | KPC | KPC | KPC | KPC | KPC/imp* |
| New York-11 | KPC | KPC | KPC | KPC | KPC | KPC | KPC |
| New York-3 | KPC | KPC | KPC | KPC | KPC | KPC | KPC |
| JS022 | NDM/CTX-M | NDM/CTX-M | NDM/CTX-M | NDM/CTX-M | NDM | NDM | NDM |
| RC-89 | NDM/CTX-M | NDM/CTX-M | NDM/CTX-M | NDM/CTX-M | NDM | NDM | NDM |
| S 3-62 | IMP | IMP | IMP | IMP | IMP | IMP | IMP |
| S5-36 | IMP | IMP | IMP | IMP | IMP | IMP | IMP |
| RC-79 | CTX-M | CTX-M | CTX-M | CTX-M | negative | negative | negative |
| EIE-UMC-1 | CTX-M | CTX-M | negative | negative | negative | negative | negative |
| RC-8 | negative | negative | negative | negative | negative | negative | negative |
| RC-16 | negative | negative | negative | negative | negative | negative | negative |
| GR-07/KP-3878 | negative | negative | negative | negative | negative | negative | negative |
| thermocycler | Biorad CFX | LC 480 | ABI 7500 | ABI 7500 | LC 480 | ABI 7500 | LC 480 |
| | | | Biorad CFX | | | | |
| polymerase | Sigma | Roche | ABI | ABI | Roche | N-Amp | Roche |
| Biorad |
1 Only CTX-M group I PCR was performed.
2 No CTX-M PCR was performed.
*: Background IMP was detected, and scored as inconclusive by laboratory 7.